🔎 Trials Near Me

Hjem › Lymfom › Massachusetts › Boston

Lymfom kliniske forsøg i Boston, MA

33 studier for Lymfom søger deltagere på steder i og omkring Boston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

RekruttererFase 1
  • Beth Israel Deaconess Medical Center - Research, Boston
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07192471

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

RekruttererFase 2
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07015242

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

Rekrutterer
  • Mass General Hospital, Boston
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07013435

Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

Rekrutterer
  • Mass General Brigham, Boston
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07014293

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

RekruttererFase 1/2
  • Dana Farber Cancer Institute., Boston
Op til 25 år · Alle køn · Opdateret 25. sep. 2026 · NCT04094610

Epco, Zanu, Ritux for R/R FL or MZL

RekruttererFase 2
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06563596

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

RekruttererFase 1/2
  • Research Site, Boston
  • Research Site, Boston
Alder 12 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06137144

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

RekruttererFase 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 21 Years · Alle køn · Opdateret 11. sep. 2026 · NCT04870944

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RekruttererFase 1/2
  • Massachusetts General Hospital, Boston
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

RekruttererFase 1/2
  • Massachusetts General Hospital, Boston
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04104776

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

RekruttererFase 4
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT07426484

The CARDIOPROTECT Trial

RekruttererFase 2
  • Beth Israel Deaconess Medical Center, Boston
Alder 18 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT07654426

DALY II USA/ MB-CART2019.1 for DLBCL

RekruttererFase 2
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

RekruttererFase 1/2
  • Call for Information (Investigational Site 0026), Boston
6 Months – 17 Years · Alle køn · Opdateret 6. jul. 2026 · NCT02332668

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

RekruttererFase 1/2
  • Dren Investigational Site, Boston
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

RekruttererObservationsstudie
  • Dana-Farber Cancer Institute, Boston
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152

Remote Monitoring and Symptom Management Digital Application

Rekrutterer
  • Massachusetts General Hospital, Boston
Alder 18 og opefter · Alle køn · Opdateret 28. apr. 2026 · NCT07553572

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Rekrutterer
  • Massachusetts General Hospital Cancer Center, Boston
Alder 18 og opefter · Alle køn · Opdateret 21. apr. 2026 · NCT05646576

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

RekruttererFase 1/2
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 16. apr. 2026 · NCT03328078

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Rekrutterer
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06923397

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

RekruttererFase 2
  • Beth Israel Deaconess Medical Center, Boston
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT06510309

Odronextamab in Low Tumor Volume Advanced FL

RekruttererFase 2
  • Beth Israel Deaconess Medical Center, Boston
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT07128641

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

RekruttererFase 2
  • Beth Israel Deaconess Medical Center, Boston
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT06510361

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

RekruttererFase 2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 5. mar. 2026 · NCT05800366

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

RekruttererFase 2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 20. feb. 2026 · NCT06854003

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

RekruttererFase 1
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 20. feb. 2026 · NCT06475235

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Rekrutterer
  • Brigham & Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 9. feb. 2026 · NCT04368702

Avo In R/R And Previously Untreated MCL

RekruttererFase 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 21. jan. 2026 · NCT04855695

Mosunetuzumab for CLL MRD Clearance

RekruttererFase 1/2
  • Brigham & Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 15. dec. 2025 · NCT07052695

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

RekruttererFase 2
  • Dana Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 5. dec. 2025 · NCT06986174

HEME Home Transfusion Program

Rekrutterer
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2025 · NCT06487247

Lymfom forsøg i andre byer

Andre studier i Boston

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.